Log In
BCIQ
Print this Print this
 

serelaxin (Reasanz) (RLX030) (formerly ConXn)

Also known as: Relaxin

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionRecombinant human relaxin 2 (RLN2; H2)
Molecular Target Relaxin 2 (RLN2) (H2)
Mechanism of ActionRelaxin receptor agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationHeart failure
Indication DetailsTreat acute heart failure (AHF)
Regulatory Designation U.S. - Breakthrough Therapy (Treat acute heart failure (AHF));
EU - Standard Review (Treat acute heart failure (AHF))
PartnerEndo International plc;
GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$620.0M

$120.0M

$500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2010

$620.0M

$120.0M

$500.0M

Get a free BioCentury trial today